Kidney function and clinical recommendations of drug dose adjustment in geriatric patients

Marlies Karsch-Völk¹, Elisa Schmid¹, Stefan Wagenpfeil²,³, Klaus Linde¹, Uwe Heemann⁴ and Antonius Schneider¹

Abstract

Background: In elderly patients chronic kidney disease often limits drug prescription. As several equations for quick assessment of kidney function by estimating glomerular filtration rate (eGFR) and several different clinical recommendations for drug dose adjustment in renal failure are published, choosing the correct approach for drug dosage is difficult for the practitioner. The aims of our study were to quantify the agreement between eGFR-equations grouped by creatinine-based or cystatin C-based and within the groups of creatinine and cystatin C-based equations and to investigate whether use of various literature and online references results in different recommendations for drug dose adjustment in renal disease in very elderly primary care patients.

Methods: We included 108 primary care patients aged 80 years and older from 11 family practices into a cross-sectional study. GFR was estimated using two serum creatinine-based equations (Cockroft-Gault, MDRD) and three serum cystatin C-based equations (Grubb, Hoek, Perkins). Concordance between different equations was quantified using intraclass correlation coefficients (ICCs). Essential changes in drug doses or discontinuation of medication were documented and compared in terms of estimated renal function as a consequence of the different eGFR-equations using five references commonly used in the US, Great Britain and Germany.

Results: In general, creatinine-based equations resulted in lower eGFR-estimation and in higher necessity of drug dose adjustment than cystatin C-based equations. Concordance was high between creatinine-based equations alone (ICCs 0.87) and between cystatin C-based equations alone (ICCs 0.90 to 0.96), and moderate between creatinine-based equations and cystatin C-based equations (ICCs 0.54 to 0.76). When comparing the five different references consulted to identify necessary drug dose adjustments we found that the numbers of drugs that necessitate dose adjustment in the case of renal impairment differed considerably. The mean number of recommended changes in drug dosage ranged between 1.9 and 2.5 per patient depending on the chosen literature reference.

Conclusions: Our data suggest that the choice of the literature source might have even greater impact on drug management than the choice of the equation used to estimate GFR alone. Efforts should be deployed to standardize methods for estimating kidney function in geriatric patients and literature recommendations on drug dose adjustment in renal failure.

Keywords: Estimated kidney function, Aged 80 years and older, Drug dose adjustment, Primary care, Literature references

Background

Family physicians see elderly multimorbid patients receiving a multiplicity of drugs on a daily basis. In many of these patients chronic kidney disease is complicating drug prescription. Family physicians are faced with the challenge to decide how to best measure renal function and draw conclusions for drug dose adjustment. It is essential that kidney function is assessed correctly and that drug doses are adjusted according to kidney function. Without drug dose adjustment in the case of impaired kidney function resulting in reduced drug clearance, drugs would accumulate and patients would be exposed to the risk of toxicity and adverse drug reactions. Therefore kidney function must not be overestimated. On the other hand, underestimation of kidney function could...
lead to underdosing or unnecessary discontinuation of potentially essential drugs.

If serum-creatinine is used alone for drug dose adjustment without calculating an estimated glomerular filtration rate (eGFR), patients are exposed to an increased risk of adverse drug reactions, because renal function can be considerably impaired despite normal serum-creatinine [1]. Serum creatinine-based equations for calculating an eGFR are important tools for identifying geriatric patients with chronic kidney disease (CKD) and for allocating appropriate drug dosage in these patients [2]. The most commonly used serum creatinine-based GFR or creatinine clearance prediction equations are the abbreviated (4-variable) Modification of Diet in Renal Disease (MDRD) [3] and the Cockroft Gault (CG) formula [4]. However, several authors point out that CG and MDRD have insufficient precision. MDRD is not suitable for identifying patients with early or moderate stages of disease, and CG tends to underestimate kidney function, especially in the elderly. Therefore these formulas should only be used with caution for drug dose adjustment in the elderly [5-8].

An alternative marker for kidney function is serum cystatin C, which has been widely examined and compared with the diagnostic use of serum creatinine. According to two meta-analyses the diagnostic accuracy of cystatin C for impaired renal function ranges between slightly and clearly better than the diagnostic accuracy of creatinine [9,10]. Especially in elderly patients, cystatin C appears to be a suitable marker for assessing renal function because there is evidence that it is less sensitive to metabolic and extra renal factors than creatinine [11].

There are a large number of cystatin C-based equations for estimating GFR. Several of these have been evaluated in elderly patients in comparison to a reference standard. Hojs et al. [12] showed, in an analysis of 234 patients aged 65 years and older, that serum creatinine-based formulas (i.e. MDRD-4-variable) had slightly lower diagnostic accuracy than cystatin C-based formulas using $^{51}$CrEDTA clearance as a reference standard. The Hoek-formula [13] had the highest accuracy and the Grubb-formula (Simple Cystatin C formula) [14], showed reasonable accuracy compared to $^{51}$CrEDTA clearance. A German study examined if there was a sufficient drug dose adjustment according to the results of several eGFR-equations based on cystatin C or creatinine in patients 60 years and older who were treated by an emergency physician. The number of patients without appropriate dose adjustment according to kidney function varied considerably depending on the equation used for calculating eGFR. This was because eGFR values themselves differed notably [16]. Swedish researchers investigated renal function in patients living in nursing homes aged 65 years and older using the CG, MDRD and Grubb equation and identified renal risk drugs. Here the authors found poor concordance between the results of different eGFR equations [17].

For patients with impaired renal function, changes in drug prescription are required. Numerous literature references for drug dose adjustment in renal impairment are commonly used in family practice in different countries. Family practitioners rely on literature that can easily be used in office or at the bedside such as small books or handheld devices [18-22].

The multitude of eGFR-equations based on serum creatinine or serum cystatin C that have been proposed and the variety of literature sources for drug dose adjustment in renal failure have resulted in uncertainty in daily practice about which method of estimating kidney function and which literature source should be used.

The aims of our study were

1) to quantify the agreement between eGFR-equations grouped by creatinine-based or cystatin C-based and within the groups of creatinine and cystatin C-based equations and

2) to investigate whether the use of various literature and online references results in different recommendations for drug dose adjustment in renal disease in very elderly primary care patients.

Methods

Patients and patient data

We included primary care patients aged 80 years and older, enlisted to 11 participating family practices in Bavaria, a federal state in southern Germany. We recruited practices by sending a letter of inquiry to the 120 teaching practices associated to the Insitute of General Practice at the Technical University Munich. Eleven practices agreed to participate. The practices were instructed to ask their patients 80 years and older if they would participate in this study. Every practice was supposed to choose at least ten patients. Patients were examined in practice, at home visits in their residence or in their nursing homes. We excluded patients unable to provide full informed consent, with thyroid dysfunction not normalized with treatment, with high dose corticosteroid therapy or with cancer, because serum cystatin C levels are influenced by these factors. As patients had to be able to give written informed consent, only patients without evidence of dementia were included. Blood samples were drawn for measuring cystatin C, creatinine, and thyroid-stimulating hormone (TSH). In addition, body height, weight, prescribed medication and diagnoses (coded according to the International Classification of Diseases (ICD)) were collected as documented in the physicians’ patient chart. All participants gave written informed consent.
Ethics statement
The study was approved by the Ethical Committee of the Medical Faculty of the Technical University Munich.

Laboratory measurements
A particle-enhanced immuno-nephelometric assay (Prospec Laboratory measurements were performed using a Sysmex analyser (XE 2100). Blood count was calculated on a pocket calculator because of its simplicity.

Estimation of glomerular filtration rate
GFR was estimated using two serum creatinine-based equations and three cystatin C-based equations which are listed below:

- **Cockcroft-Gault equation:**
  \[
  \text{eGFR}_{\text{ml/min}/1.73\text{m}^2} = \left( \frac{140-\text{age (years)}}{\text{weight (kg)}} \right) \times \frac{72 \times \text{CREA}_{\text{mg/dl}} \times 1.73 / \text{body surface area}_{\text{m}^2}}{72}
  \]

- **MDRD equation:**
  \[
  \text{eGFR}_{\text{ml/min}/1.73\text{m}^2} = 175 \times \left( \frac{\text{CREA}_{\text{mg/dl}}}{1.154} \right)^{1.154} \times \left( \frac{\text{age (years)}}{0.209} \right) \times 0.742 \text{ for women} \]

- **Grubb equation:**
  \[
  \text{eGFR}_{\text{ml/min}/1.73\text{m}^2} = 84.69 \times \text{cystatin C}_{\text{mg/l}}^{1.680} \times 0.948 \text{ if female} \]

- **Hoek equation:**
  \[
  \text{eGFR}_{\text{ml/min}/1.73\text{m}^2} = -4.32 + 80.35 / \text{cystatin C}_{\text{mg/l}} \]

- **Perkins equation:**
  \[
  \text{eGFR}_{\text{ml/min}/1.73\text{m}^2} = 100 / \text{cystatin C}_{\text{mg/l}} \]

Serum creatinine-based equations were the **CG equation** [4] (adjusted for body surface area by the DuBois formula [23]: \( \text{BSA}_{\text{m}^2} = 0.007184 \times \text{height}_{\text{cm}}^{0.725} \times \text{weight}_{\text{kg}}^{0.425} \)) and the abbreviated (4-variable) **MDRD** [3]. The cystatin C-based eGFR-equations were the **Grubb equation** [14], the **Hoek equation** [13], and the **Perkins equation** (Simple Cystatin C formula) [15]. The CG and MDRD equation were chosen because they are commonly in use and well known to practitioners. Two cystatin C-based equations (Hoek and Grubb) were chosen because they were developed on data from European study populations and therefore seemed suitable for our study population. The Perkins equation was chosen because its use would be practical for daily use also on home visits as it can easily be calculated on a pocket calculator because of its simplicity.

**Verification of drug dose adjustment to renal function**
For each eGFR-value, each patient's drug doses of his or her actually prescribed medication according to estimated renal function were verified using several literature references. In our study, five different references, mentioned in the Background section were consulted. We chose references that are easily accessible and commonly used in daily clinical practice: (e.g. in the U.S. [18], in Great Britain [19,20] and in Germany [21,22]). More extensive pharmaceutic literature references were not included as we aimed to examine tools that are suitable for daily use in medical practice. Essential changes in drug doses or discontinuation of medication were documented and compared in terms of estimated renal function as a consequence of the different eGFR-equations.

Each participating family practice received a detailed report about every single patient including results of laboratory tests, estimated kidney function according to different equations and recommendations on adjustment of the prescribed drugs according to eGFR results and literature recommendations. We did not assess if participating family practitioners implemented our recommendations.

**Statistical analysis**
All statistical analyses were performed using SPSS statistical software (SPSS 18.0 and 19.0, IBM, Somers, NY). Patient data was summarized descriptively (percentage, mean, median standard deviations and minimum/maximum). We created scatter plots to graphically examine concordance between the different eGFR estimations, including a linear trend regression as well as a bisecting line. Concordance was further analysed by calculating intra-class correlation coefficients (ICCs, two-way mixed model) along with a respective 95% confidence interval. Comparisons concerning the numbers of drugs that may require dose adjustments were done using the two-sided Friedman- or Wilcoxon-test, as appropriate. Agreement beyond chance between different literature and online sources regarding the necessity of drug dose adjustment was quantified with kappa statistic. Kappa values < 0.4 were considered as low agreement, values between 0.4 to 0.59 as moderate, 0.6 to 0.74 as good and higher as very good agreement.

**Results**
A total of 108 patients, 73% female with a mean age of 85 years, were included in the study. The number of patients enlisted from each individual practice ranged from one to 25 patients. On average five patients per practice
were included. Patient characteristics, frequent diagnoses and drugs, and laboratory measures are summarized in Tables 1, 2 and 3. Chronic kidney failure was documented a priori for 32 patients (30%) in the general practitioners’ patient records. It was not possible to determine if drug dose adjustment was done before by the general practitioners in that group due to kidney function or due to other reasons. The three most frequent diagnoses (prevalence over 50%) were hypertension, arthrosis and cardiac failure. Due to exclusion of patients unable to provide written informed consent, the proportion of patients suffering from dementia and the proportion of patients taking psychotropic substances were comparatively low. Most commonly taken remedies (taken by more than 50% of the patients) were angiotensin-converting enzyme inhibitors, hydrochlorothiazide and beta-adrenoceptor blockers. Some of these drugs may require drug dose adjustment in renal impairment as shown in Table 3.

The lowest median estimate of renal function resulted from the use of the creatinine-based CG and MDRD equations and the highest from the cystatin C-based Perkins-equation (Table 1, lower section). High concordance was observed between the creatinine-based equations alone and between the cystatin C-based equations alone (Table 4). Concordance between creatinine-based equations and cystatin C-based equations was moderate. Scatterplots illustrating the relation between the results of the two creatinine-based and the three cystatin C-based equations are presented in Figure 1. Concordance was highest between the creatinine-based equations and the Hoek equation, and lowest between the creatinine-based equations and the Grubb equation.

When comparing the five different references consulted to identify necessary drug dose adjustment in relation to the estimated kidney function, we found that the number of drugs that necessitate a dose adjustment in case of renal impairment differ considerably (Table 5). “Drug Prescribing in Renal Failure” and “Arzneimittel Pocket” identify the highest number of drugs which need to be adjusted following renal impairment. None of the literature references contained information on all drugs taken by the study patients.

Agreement and disagreement in recommendations regarding the number of medication changes according to the different literature and online references is exemplarily shown for the results of the CG equation in Table 6. If a literature reference did not provide information about drug dose adjustment for a certain drug, we rated it as “no change necessary”. This approach was chosen because we assumed that a practitioner would not adjust the drug dose in that case. Kappa values ranged between 0.10 and 0.62 with the majority of values below 0.40 (indicating low agreement beyond chance). Testing Kappa coefficients with regard to other eGFR estimations yielded similar results. Descriptive analysis also shows differences in recommendations according to literature references (not shown in table). For example, according to “The Renal Drug Handbook” a change of drug prescription is recommended in 6 to 12 patients depending on the formula used, while according to “Drug Prescribing in Renal Failure” the number of patients varies between 21 and 27. In addition, partially conflicting recommendations were found.

**Table 1 Physical and biochemical patient characteristics**

|                        | N = 108 | N (%) or Median (range) |
|------------------------|---------|-------------------------|
| Female sex             | 79 (73) |
| Age (years)            | 85 (80-102) |
| Body Mass Index (kg/m²)| 26.0 (16.7-47.1) |
| Number of diagnoses    | 9 (2-17) |
| Number of drugs/day    | 7 (1-19) |
| Creatinine (mg/dl)     | 1.0 (0.5-3.2) |
| Cystatin C (mg/l)      | 1.2 (0.6-3.4) |
| eGFR Cockroft-Gault (ml/min/1.73 m²) | 45.3 (12.2-95.8) |
| eGFR MDRD (ml/min/1.73 m²) | 53.2 (14.8-118.1) |
| eGFR Grubb (ml/min/1.73 m²) | 63.5 (11.1-174.5) |
| eGFR Hoek (ml/min/1.73 m²) | 65.5 (19.7-123.2) |
| eGFR Perkins (ml/min/1.73 m²) | 87.0 (29.9-158.7) |

**Table 2 Most common diagnoses as documented in patient charts as coded in ICD 10**

|                         | N (%) |
|-------------------------|-------|
| Hypertension            | 94 (87) |
| Arthrosis               | 58 (54) |
| Cardiac failure         | 54 (50) |
| Hyperlipidemia          | 49 (45) |
| Type 2 diabetes mellitus| 43 (40) |
| Coronary heart disease  | 35 (32) |
| Chronic kidney failure (no dialysis required) | 32 (30) |
| Hyperuricemia           | 29 (27) |
| Atrial fibrillation     | 21 (19) |
| Incontinence            | 21 (19) |
| Peripheral artery occlusive disease | 21 (19) |
| Struma                  | 19 (18) |
| Dementia                | 13 (12) |
| Chronic obstructive pulmonal disease (COPD) | 12 (11) |

**Discussion**

We found that cystatin C-based equations resulted in more optimistic estimations of kidney function than the creatinine-based ones. However, variations in
recommendations according to the different literature sources led to more variations in drug dose adjustment than the different GFR-equations alone.

In general creatinine-based equations resulted in a lower eGFR-estimation and in a higher necessity of drug dose adjustment than Cystatin C-based equations. The CG equation resulted in the lowest and the Perkins equation in the highest estimation of kidney-function. Several trials showed that kidney function in elderly patients is estimated to be lower or even underestimated by the CG equation compared to the 4-variable MDRD equation \[2,7,24,25\]. Results concerning differences in accuracy of CG and MDRD equations in senior patients are inconsistent. Some trials showed higher precision for MDRD than CG when compared with a reference standard \[25-27\]. Other studies using a reference standard found a lack of precision in both formulas in elderly patients \[6,24\].

There is little data about the use of cystatin C-based GFR-equations in very old patients. Systematic reviews comparing several studies about diagnostic accuracy of serum cystatin C and serum creatinine for diagnosing renal failure found more studies favouring cystatin C, or describing cystatin C as equal, than those favouring creatinine \[28,29\]. A systematic review \[30\] analysed 12 studies comparing serum creatinine, CG equation, MDRD equation, serum cystatin C and several different GFR equations with a reference standard in elderly patients aged 65 years and older. The CG and MDRD equations and the serum cystatin C equations produced the highest correlations with the reference standard. Serum creatinine correlated poorly with the reference standard and therefore appeared to be an insensitive tool for measuring renal function in the elderly.

The impact on drug dose adjustment in four defined drug classes (metformin, nonsteroidal anti-inflammatory drugs, angiotensin-converting-enzyme-inhibitors/angiotensin receptor blockers, and digoxin) depending on different equations was analysed in a Swedish study \[17\]. As mentioned above, this study also found a lack of concordance between MDRD, CG and the Grubb equation, but the investigated renal risk drugs were rarely prescribed.

In addition to the estimated kidney function, the chosen literature source had a strong impact on the recommendations for drug dose adjustment in our study population. Kappa coefficients reveal a lack of accordance between the recommendations according to the various literature sources. Depending on the literature source, different numbers of drugs are to be adjusted following renal impairment. Also the recommendations concerning critical values of GFR requiring drug dose adjustment differed considerably among the different sources. The use of “Arzneimittel Pocket” resulted in the highest number of advised modifications of medication and the use of “The Renal Drug Handbook” in the

### Table 3 Most commonly taken remedies

| N = 108 | N (%) |
|---------|-------|
| Angiotensin-converting enzyme inhibitor* | 59 (55) |
| Hydrochlorothiazide* | 59 (55) |
| Beta-adrenoceptor blocker** | 54 (50) |
| Acetylsalicylic acid* | 41 (38) |
| Non steroidal anti inflammatory drugs* | 23 (21) |
| Statins** | 22 (20) |
| Antidepressants** | 18 (17) |
| Opioids** | 18 (17) |
| Sartans** | 17 (16) |
| Allopurinol* | 10 (9) |
| Bisphosphonates* | 8 (7) |
| Neuroleptics** | 8 (7) |
| Sulfinylureas* | 8 (7) |
| Acetaminophen (Paracetamol)* | 7 (7) |
| Metformin* | 7 (7) |
| Metoclopramide* | 7 (7) |
| Aldosterone antagonists* | 4 (4) |
| Antidementives** | 2 (2) |
| Antiplatelets** | 2 (2) |
| Alpha2 adrenergic receptor antagonists* | 2 (2) |
| Digoxin* | 2 (2) |
| H2 receptor antagonists* | 2 (2) |
| Disease modifying antirheumatic drugs** | 2 (2) |

* All drugs in this class require dose adjustment in case of moderate or severe renal impairment.

** Some drugs of this class require dose adjustment in case of renal impairment.

### Table 4 Intraclass-correlation coefficients for eGFR according to different equations

| eGFR (ml/min/1.73 m²) | CG (95% CI) | Hoek (95% CI) | Grubb (95% CI) | Perkins (95% CI) |
|----------------------|------------|---------------|---------------|------------------|
| MDRD                 | 0.87 (0.81-0.91) | 0.76 (0.66-0.83) | 0.65 (0.53-0.75) | 0.73 (0.63-0.81) |
| CG                   | 0.69 (0.57-0.78) | 0.54 (0.39-0.66) | 0.63 (0.50-0.73) | 0.98 (0.97-0.98) |
| Hoek                 | 0.90 (0.85-0.93) | 0.96 (0.95-0.98) |                |                  |
| Grubb                | 0.96 (0.95-0.98) |                |                |                  |

CG = Cockroft-Gault; MDRD = Modification of Diet in Renal Disease; 95% CI = 95% confidence interval.
It is unclear why the recommendations are diverging to such an extent. Three of the literature sources (The Renal Drug Handbook, Arzneimittel Pocket and Dosing) have been written by one or more authors and two (British National Formulary and Drug Prescribing in Renal Failure) have been developed by expert panels. All authors point out that they are referring to the newest evidence. The broad variation of results of estimated kidney function and of the recommendations given in different literature and online sources creates an uncertainty for the practitioner. The extent of the risk potential resulting from medication with renal risk drugs for the elderly is unclear.

For daily practice it seems reasonable to use the CG equation as a more conservative approach to dose adjustment in renal impairment. But it is important to keep in mind that there is a risk of underdosing due to the fact that the CG equation tends to underestimate kidney function in the elderly. In borderline cases (e.g. if a drug should be reduced in the case of an eGFR of less than 30 ml/min/1.73 m² and the use of CG is resulting in an eGFR of 29 ml/min/1.73 m²) another equation should be used for control. In this case MDRD would work well. In cases where kidney function is over 60 ml/min/1.73 m², a cystatin C-based formula could be used. The use of the Grubb equation makes sense in this case, as it is resulting in a more conservative estimation of kidney function. But we cannot give a clear recommendation, as there are many other creatinine- and cystatin C-based equations that have not been examined in our study.

Regarding the literature recommendations it appears difficult to suggest the use of one particular literature reference since none of the references is covering all of the relevant cases.
the renal risk drugs. It seems rational to use country related references as they are the most likely to coincide with national guidelines.

A strength of our study is that it was conducted under conditions of routine practice and focused on the consequences for the daily work of a family physician. We examined patients at eighty years of age and older because multimorbidity, polypharmacy and renal impairment are common in this group of patients and, according to literature, it remains unclear which eGFR-estimation is suitable for estimating kidney function. The four literature references and the online-source analysed are easily accessible for practitioners and commonly in use. There are differences in the estimated prevalence of impaired renal function depending on the eGFR-equation applied, and reduced kidney function seems to be common in our study population. A limitation of our study is that kidney function was not determined by inulin-clearance, $^{51}$Cr-EDTA-clearance, or iohexol-clearance, which are reference standards. However, this was not possible in the primary care setting. But this could not hamper our results related to the heterogeneity of eGFR equations which are originally derived by validation compared to a reference standard. Another limitation is that patients included had to be able to give written informed consent, therefore patients suffering from dementia or severe frailty, could not be examined. As a result, our study population is not fully representative for the age group as the examined patients were in relatively good mental condition. Another limitation of the study may be that we restricted the number of literature references on drug dose adjustment in renal failure to five commonly in use. However, we explicitly wanted to examine practice conditions and examine tools that are easy to apply and can also be used on home visits.

### Table 5 Differences in the number of drugs that may require dose adjustment in kidney failure per patient according to the five literature sources

| Nr. of Drugs | Renal Drug HB | Dosing | AMP | BNF | DPRF |
|--------------|--------------|--------|-----|-----|------|
| 0            | 7 (6%)       | 4 (13%)| 9 (8%)| 11 (10%)| 7 (7%)|
| 1            | 37 (34%)     | 19 (18%)| 18 (17%)| 23 (21%)| 16 (15%)|
| 2            | 33 (31%)     | 40 (37%)| 28 (26%)| 40 (37%)| 34 (32%)|
| 3            | 21 (19%)     | 25 (23%)| 36 (33%)| 25 (23%)| 31 (29%)|
| 4            | 9 (8%)       | 7 (6%)| 13 (12%)| 7 (7%)| 12 (11%)|
| 5            | 1 (1%)       | 3 (3%)| 3 (3%)| 1 (1%)| 5 (5%)|
| 6            |              | 1 (1%)| 0 (0%)| 3 (3%)|      |
| 7            |              |        |        | 1 (1%)|      |

M (SD) = 1.92 (1.10) 2.01 (1.20) 2.36 (1.26) 2.02 (1.20) 2.48 (1.34)

Friedman-test for comparison of all literature sources: p < 0.001; Wilcoxon-test paired samples: p < 0.001 for Renal Drug HB vs. AMP, Dosing vs. AMP, Renal Drug HB vs. DPRF, Dosing vs.DPRF, AMP vs. BNF, BNF vs. DPRF, and p = 0.39 for Renal Drug HB vs. Dosing, p = 0.36 for RDB vs. BNF, p = 0.95 for Dosing vs. BNF, p = 0.22 for AMP vs. DPRF;

M = Mean, SD = Standard deviation;
Renal Drug HB = The Renal Drug Handbook (19), Dosing = www.dosing.de (21), AMP = Arzneimittel Pocket (22), BNF = British National Formulary (20), DPRF = Drug Prescribing in Renal Failure (18).

### Table 6 Agreement beyond chance (Kappa coefficients) among different references regarding necessary drug changes when using the Cockroft-Gault equation for estimating eGFR

|          | Dosing (95% CI) | AMP (95% CI) | BNF (95% CI) | DPRF (95% CI) |
|----------|----------------|--------------|--------------|---------------|
| Renal Drug HB | 0.15 (0.00-0.32) | 0.10 (0.00-0.34) | 0.23 (0.06-0.40) | 0.20 (0.03-0.36) |
| Dosing    | 0.62 (0.47-0.78) | 0.51 (0.35-0.68) | 0.19 (0.02-0.35) |               |
| AMP       |                | 0.49 (0.34-0.65) | 0.19 (0.05-0.34) |               |
| BNF       |                | 0.57 (0.40-0.73) |               |               |

95% CI = 95% confidence interval;
Renal Drug HB = The Renal Drug Handbook (19), Dosing = www.dosing.de (21), AMP = Arzneimittel Pocket (22), BNF = British National Formulary (20), DPRF = Drug Prescribing in Renal Failure (18).

Conclusions

The chosen literature references resulted in bigger differences in recommendations for drug dose adjustment than the different equations used for estimating eGFR alone. Both, the divergent results of the eGFR equations and the conflicting instructions according to the literature sources can lead to uncertainty for the practitioner and as a result compromise patient safety. Thus there is a strong need for a validated eGFR-equation for estimating kidney function in the elderly. Further research on estimation of GFR and the development of an international consensus on concordant recommendations for practitioners concerning drug dose adjustment in renal failure are desirable.
Abbreviations
AMP: Arzneimittel pocket [22]; BNF: British National Formulary 20; BSA: Body surface area; CG: Cockcroft-Gault; CI: Confidence interval; CKD: Chronic kidney disease; CREA: Creatinine; Dosing: www.dosing.de [21]; DFRP: Drug Prescribing in Renal Failure [18]; eGFR: Estimated glomerular filtration rate; GFR: Glomerular filtration rate; ICCs: Intraclass correlation coefficients; M: Mean; MDRD: Modification of Diet in Renal Disease; N: Number of patients; Renal Drug HB: The Renal Drug Handbook [19]; SD: Standard deviation; TSH: Thyroid-stimulating hormone.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
MKV wrote the study protocol, was the study supervisor and was responsible for technical and material support, participated in data collection, participated in the analysis and interpretation of data, and drafted the manuscript. ES collected data and helped to write the manuscript. All authors commented on draft versions and read and approved the final manuscript. ES: data and helped to write the manuscript. MKV wrote the study protocol, was the study supervisor and was responsible for technical and material support, participated in data collection, performed the statistical analysis and wrote the manuscript. UE contributed to the interpretation of the data. AS conceived the study, contributed to study protocol, was involved in analysis and interpretation of data and helped to write the manuscript. All authors commented on draft versions and read and approved the final manuscript.

Acknowledgements
Part of this work was performed for the MD thesis of Elisa Schmid at the Technische Universität München. We would also like to thank the 11 family practitioners for their participation in this study. The authors did not receive any funding.

Author details
1 Institute of General Practice, University Hospital Klinikum rechts der Isar, Technische Universität München, Munich, Germany. 2 Institute for Medical Biometry, Epidemiology and Medical Informatics (IMBEI), Universitätsklinikum des Saarlandes, Homburg/Saar, Germany. 3 Department of Nephrology, University Hospital Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

Received: 15 March 2013 Accepted: 6 September 2013

References
1. Coronel N, Pedone C, Cottica F, Musi C, Carbonin P, Antonelli Incalzi R: Conceived renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med 2005, 165:790–795.
2. Kural H, Schwenger V, Azzaro M, Abdollahnia N, Steinhausen-Thiessen E, Niecza J, et al: Clinical value of automatic reporting of estimated glomerular filtration rate in geriatrics. Gerontologist 2009, 55:288–295.
3. Levey AS, Coresh J, Greene T: A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000, 11(Suppl):155A.
4. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:1–41.
5. Garg AX, Papaioannou A, Ferko N, Campbell G, Clarke JA, Ray JG: Estimating the prevalence of renal insufficiency in seniors requiring long-term care. Kidney Int 2004, 65:649–653.
6. Rimon E, Kaganovska N, Cicojacka L, Gindlin J, Schattner A, Levy S: Can creatinine clearance be accurately predicted by formulae in octogenarian in-patients? QJM 2004, 97:281–287.
7. Gouin-Thibault I, Pautois E, Malhe I, Descarpentaires C, Nivet-Antoine V, Golmaria JL, et al: Is Modification of Diet in Renal Disease formula similar to Cockcroft-Gault formula to assess renal function in elderly hospitalized patients treated with low-molecular-weight heparin? J Gerontol A Biol Sci Med Sci 2007, 62:1300–1305.
8. Gill J, Malyuk R, Djurdevic O, Levin A: Use of GFR equations to adjust drug doses in an elderly multi-ethnic group—a cautionary tale. Nephrol Dial Transplant 2007, 22:2894–2899.
9. Dhamidhaka VR, Kwn C, Stevens G: Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002, 40:221–226.
10. Roos JF, Doust J, Tett SE, Kirkpatrick CM: Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in children and adults – a meta-analysis. Clin Biochem 2007, 40:389–391.
11. Seronie-Vivien S, Delanaye P, Pieron L, Mariat C, Frossard M, Cristol JP: Cystatin C: current position and future prospects. Clin Chem Lab Med 2008, 46:1664–1686.
12. Hojs R, Blašk S, Eklart R, Gorenjak M, Pulvavec L: Serum cystatin C-based formulas for prediction of glomerular filtration rate in patients with chronic kidney disease. Nephron Clin Pract 2010, 114:c118–c126.
13. Ho JS, Kempen FA, Kreder RT: A comparison between cystatin C plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003, 18:2024–2031.
14. Grubb A, Nyman U, Bjork J, Lindstrom V, Rippe B, Sterner G, et al: Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Cockroft-Gault prediction equations for children. Clin Chem 2005, 51:1420–1431.
15. Perkins BA, Nelson RG, Ostrander BE, Blouch KL, Krolewski AS, Myers BD, et al: Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 2005, 16:1404–1412.
16. Bohrkinr J, Schiedensack G, Kolisch M, Brecvoldt J, Antcz HR, Kreutz R: Anthypertensive drug treatment and renal function in geriatric emergency patients. Dtsch Med Wochenschr 2009, 134:802–806.
17. Modig S, Lanning C, Ostgren CJ, Midlo M, Midlow P: The assessment of renal function in relation to the use of drugs in elderly in nursing homes; a cohort study. BMC Geriatr 2011, 11:11.
18. Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, Pasko DA, Smoyer WE: Drug Prescribing in Renal Failure – Dosing Guidelines for Adults and Children. 5th edition. Philadelphia: American College of Physicians; 2011.
19. Ashley C, Currie A: The Renal Drug Handbook. 3rd edition. Oxford, New York: Radcliffe Publishing Ltd; 2009.
20. BMI Group and Royal Pharmaceutical Society of Great Britain: British National Formulary. 61st edition. London: Pharmaceutical Press, 2011.
21. Haefteli WE: Dosing. http://www.dosing.de. (last accessed: 23-2-2012).
22. Ruβ A: Arneimittel pocket 2010. 15th edition. Gränovald: Börm Bruckmeier Verlag; 2009.
23. Dubois D, Du, Bois FE: A formula to estimate the approximate surface area if height and weight be known. Arch Int Med 1916, 17:863–871.
24. Lamb EW, Browe HI, O’Riordan SE, Webb MC, Dalton RN: Susceptibility of glomerular filtration rate estimations to variations in creatinine methodology: a study in older patients. Ann Clin Biochem 2005, 42(Pt 1):111–118.
25. Lamb EW, Webb MC, O’Riordan SE: Using the modification of diet in renal disease (MDRD) and Cockcroft and Gault equations to estimate glomerular filtration rate (GFR) in older people. Age Ageing 2007, 36:689–692.
26. Feinman-Ehholm J, Skeppholm L: Renal function in the elderly (>70 years old) measured by means of inohexol clearance, serum creatinine, serum urea and estimated clearance. Scand J Urol Nephrol 2004, 38:73–77.
27. Frossard M, Rosset J, Jacquet C, Paillard M, Moulin C: Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005, 16:763–773.
28. Laterza OF, Price CP, Scott MG: Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 2002, 48:699–707.
29. Zahn H, El-Hussein A, Shoker A: Can cystatin C replace creatinine to estimate glomerular filtration rate? A literature review. Am J Nephrol 2007, 27:197–205.
30. Van Pottelbergh G, Van HL, Mathei C, Degryse J: Methods to evaluate renal function in elderly patients: a systematic literature review. Age Ageing 2010, 39:542–548.

Cite this article as: Karsch-Völk et al.: Kidney function and clinical recommendations of drug dose adjustment in geriatric patients. BMC Geriatrics 2013 13:92.